Take a look at the research highlights of 2019 as we count down the top infectious disease stories from A to Z!
Browsing: Disease Area > Bacterial
In this interview, we speak to Jenn Edwards from the Abigail Wexner Research Institute (OH, USA) about her research using the primary human epithelial cell models to examine Neisseria gonorrhoeae infections, the potential for vaccination against gonorrhea and a possible host-targeted therapy for this infection.
Researchers have uncovered a novel mechanism utilized by group A streptococcus that allows it to evade detection by the immune system in infected mice, providing insight for the development of effective countermeasures against this pathogen.
Take a look at this month’s industry headlines including results for Takeda’s dengue vaccine, approvals for Merck’s Ebola vaccine and the advent of a siderophore antibiotic – the first of this kind.
A new study from Washington University School of Medicine in St. Louis reveals how the household environment can influence the transmission dynamics of methicillin-resistant Staphylococcus aureus.
New research indicates that harnessing RNA sensors could allow human cells to be more attuned to killing tuberculosis, presenting an effective means for controlling the spread of the disease.
A study published today in the Journal of the America Medical Informatics Association has demonstrated that a new digital sepsis monitoring system implemented in three Imperial College Healthcare NHS Trust (London, UK) hospitals lowered the odds of death from sepsis by 24%.
The US FDA has approved cefiderocol (Fetroja), a siderophore cephalosporin that inhibits bacterial cell wall synthesis. Fetroja is the first approved antibiotic that functions as a siderophore.
A team including University of Maryland and University of Texas Medical Branch researchers have found that two bacterial strains interact to cause a severe flesh-eating infection, highlighting the need to consider variant strains of a single species when administering antibiotics.
Research published today in Infection and Immunity suggests a novel vaccine for Staphylococcus aureus may be on the horizon, with the candidate protecting 80% of immunized mice.